Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and Older

2006 ◽  
Vol 19 (4) ◽  
pp. 456-465 ◽  
Author(s):  
H.A. Tiddens ◽  
D.E. Geller ◽  
P. Challoner ◽  
R.J. Speirs ◽  
K.C. Kesser ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults

2004 ◽  
Vol 20 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Edwin A. Bronsky ◽  
Jay Grossman ◽  
Marc J. Henis ◽  
Paul P. Gallo ◽  
Ümit Yegen ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Asthmatic Children

scholarly journals Clinical effect of Diskus™ dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children

1998 ◽  
Vol 11 (2) ◽  
pp. 350-354 ◽  
Author(s):  
K. G. Nielsen ◽  
I. L. Auk ◽  
K. Bojsen ◽  
M. Ifversen ◽  
B. Klug ◽  
...  
Keyword(s):  
Clinical Effect ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Asthmatic Children

Peak Inspiratory Flow Rates Generated through The Novolizer® And The Turbuhaler® Dry Powder Inhaler Devices by Children with Stable Asthma

2007 ◽  
Vol 20 (1) ◽  
pp. 50-58 ◽  
Author(s):  
Andrea Von Berg ◽  
Hans-Joachim Kremer ◽  
Barbara Ellers-Lenz ◽  
Frank Conrad ◽  
Katharina Erb ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Peak Inspiratory Flow ◽  
Inhaler Devices

scholarly journals Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device

2014 ◽  
Vol 8 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Mark R. Elkins ◽  
Philip Robinson ◽  
Sandra D. Anderson ◽  
Clare P. Perry ◽  
Evangelia Daviskas ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Inhaler Device ◽  
Device Resistance ◽  
In Series ◽  
Efficient Alternative ◽  
The Mean

Introduction: Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (≥ 45L/min) inspiratory flows and volumes generated by individuals. Dry-powder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if CF patients’ inspiratory flows and volumes are adequate to use the RS01 DPI device. Materials and Methodology: An open, non-interventional study; enrolled 25 CF subjects, aged ≥ 6 years with FEV1 ≥ 30 to < 90‰ predicted. Inspiratory flows and volumes were measured when subjects inhaled in a controlled manner through the RS01 device in series with a spirometer. Results: The mean inspiratory volume (IV) of CF subjects was 1.83L ± 0.97. Their achieved mean ± SD peak inspiratory flow (PIF) was 75.5 ± 27.2L/min. Twenty-three subjects (92%) achieved PIF of > 45L/min with the inhaler device; eighteen of those subjects (78%) had a baseline FEV1 of > 1L. Conclusion: Use of the RS01 DPI device allowed adequate inspiratory flow and volume for dispersion of dry-powder mannitol in CF patients.

A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness

2021 ◽  
Vol 42 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Donald P. Tashkin ◽  
Arkady Koltun ◽  
Róisín Wallace
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Fluticasone Propionate ◽  
Healthy Volunteers ◽  
Pulmonary Disease ◽  
Dry Powder Inhaler ◽  
Chemical Degradation ◽  
Chronic Obstructive ◽  
Dry Powder ◽  
Obstructive Pulmonary Disease ◽  
Flow Rates

Background: A generic combination of fluticasone propionate and salmeterol xinafoate inhalation powder in a premetered, multidose, nonreusable inhaler was recently approved. Objective: To assess the performance of the generic device. Methods: Findings from three studies with regard to device usability, function, and robustness were reviewed. Results: In a study to assess device function in patients and healthy volunteers, the generic device was successfully used by patients with asthma and chronic obstructive pulmonary disease who were either dry powder inhaler users or dry powder inhaler‐naive, even though they were not trained beyond being provided the instructions for use. In a study to measure inhaled flow rates generated by patients and healthy volunteers, the generic device consistently simulated the delivery of a full dose of drug, even to patients with severe respiratory disease and reduced inspiratory flow rates. Although the generic device had a slightly higher airflow resistance, this study demonstrated that this difference did not result in any clinically meaningful differences in terms of drug delivery. Pressure drop, a key parameter that drives the fluidization and aerosolization of the powder dose, was found to be comparable between the devices. In an open-label study, the generic device met all U.S. Food and Drug Administration specifications for device robustness after 21.5 days of twice-daily dosing via oral inhalation among 111 participants with asthma or chronic obstructive pulmonary disease. All inhalers tested demonstrated conformity with a pharmacopeia with respect to key quality parameters (assay, delivered dose uniformity, aerodynamic size distribution). There was no evidence of chemical degradation of the active ingredients, nor of microbial or water ingress into the powder, as a result of inhaler use.

Development of cefdinir loaded Functionalized carbon Nanotubes dry powder Inhaler for the Treatment of cystic Fibrosis

2021 ◽  
pp. 3839-3845
Author(s):  
Krishnat D. Dhekale ◽  
Ravindra N. Kamble
Keyword(s):  
Carbon Nanotubes ◽  
Cystic Fibrosis ◽  
Drug Loading ◽  
Dry Powder Inhaler ◽  
Dry Powder ◽  
Efficient Treatment ◽  
Multi Walled Carbon Nanotubes ◽  
Stable Product ◽  
Lung Infections ◽  
Walled Carbon Nanotubes

A dry-powder inhaler (DPI) carries medication to lungs as a dry powder, useful against respiratory diseases. The current research was endeavoured to examine the capabilities of Multi-walled carbon nanotubes (MWCNT) as a pulmonary transporter for directing cefdinir to cystic fibrosis (CF). Functionalized MWCNTs were loaded with cefdinir to formulate DPI (F-CEF FMWCNTs DPI) having efficient treatment against lung infections and were evaluated successfully. The outcomes demonstrated that cefdinir loaded FMWCNTs were non-toxic and accomplished 79.73 % entrapment with better flow properties. The optimized formulation had Mass Median Aerodynamic Diameter (MMAD), Fine particle fraction (FPF), and particle size of 3.45±0.09 μm, 58.52±1.06%, 5.25 ± 0.03 μm (CEF FMWCNT DPI) and 4. 29±0.16μm 38.74±1.02%, 7.54 ± 0.02 μm (C-DPI) respectively. The loaded nanotubes showed 72. 63 % release after 15 hours in a controlled manner. The outcome of work recognized a unique, simple, and stable product having improved drug loading and increased dispersibility of carbon nanotubes (CNTs) thus improved bioavailability at a lung infection place with less adverse actions.

Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis

2019 ◽  
Vol 32 (3) ◽  
pp. 156-163
Author(s):  
Heino Stass ◽  
Johannes Nagelschmitz ◽  
Dominik Kappeler ◽  
Knut Sommerer ◽  
Astrid Patzlaff ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Inspiratory Flow ◽  
Dry Powder
Sign in / Sign up

Export Citation Format

Share Document